Rare Medical News
Advertisement
Spotlight On
Sjögren’s syndrome
Sjögren's syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva
Prevalence
7-10/100,000
23,170 - 35,945
Us Estimated
33,100 - 51,350
Europe estimated
Age of Onset
ICD-10
M35. 0
Inheritance
This condition does not appear to have a clear pattern of inheritance.
Rare View
Sjögren’s syndrome is a chronic autoimmune disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body. The main symptoms are dry eyes and mouth, but other parts of the body may be affected as well, with many people reporting fatigue and joint and muscle pain. In addition, the disease can damage the lungs, kidneys, and nervous system. Sjögren’s syndrome predominantly affects women.†
5 Facts you should know
FACT
Autoimmune disease that affects the body's moisture-producing glands
FACT
The hallmark symptom of Sjögren syndrome is dry mouth and keratoconjunctivitis sicca
FACT
Other symptoms can include dry skin, vaginal dryness, a chronic cough, numbness in the arms and legs, feeling tired, muscle and joint pains, and thyroid problems
FACT
Sjögren's syndrome may be associated with other autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or systemic sclerosis
FACT
Those affected are also at an increased risk (15%) of lymphoma
Interest over time
Google searches
Common signs & symptoms
The most common symptoms are:
- Dry eyes.Your eyes may burn or itch or feel like they have sand in them. Sometimes, the dryness causes blurry vision or sensitivity to bright light. You may get irritated, itchy eyelids due to inflammation.
- Dry mouth.Your mouth may feel chalky, and you may have trouble swallowing, speaking, and tasting. You may develop more cavities and mouth infections.
In some cases, Sjögren’s syndrome affects other tissues and organs and has more widespread effects on the body. These other effects may cause:
Fatigue (feeling very tired)
Joint pain and muscle aches and weakness
Dry skin, nasal passages, and throat, and a dry cough
Skin rashes
Swelling of the glands around the face and neck
Trouble sleeping
Poor concentration and memory problems
Numbness, tingling, and weakness, especially in your arms and legs
Shortness of breath or trouble breathing
Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Current treatments
There is no cure for Sjögren’s syndrome, so treatment focuses on relieving symptoms and preventing complications. Treatments are different for each person and will depend on which parts of the body are affected.
Eye treatments:
Eye drops (artificial tears)
Some people need prescription eye drops that contain medications to suppress the immune system and reduce inflammation in the eye.
Eye ointments
Punctal occlusion
Small plugs placed in the tear duct in the corners of the eyes block drainage and keep tears in the eyes longer.
Mouth treatments:
Artificial saliva
Saliva production stimulators
Cevimeline (Evoxac)
Pilocarpine (Salagen)
Anti-fungal medications
Top Clinical Trials
| Title | Description | Phases | Status | Interventions | More Information |
|---|---|---|---|---|---|
| Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome | A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2) | Phase 3 | Active | Biological: VAY736 Other: Placebo | More Info |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome. | Phase 3 | Active | Drug: Deucravacitinib Other: Placebo | More Info |
| Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity | This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD). | Phase 2 | Active | Drug: IMVT-1402 Drug: Placebo | More Info |
| A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's | This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease. | Phase 2 | Active | Biological: Sibeprenlimab Other: Placebo | More Info |
| A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome | This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome. | Phase 2 | Not yet recruiting | Drug: ESG206 Drug: Placebo | More Info |
| Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease | Background: Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs. It can also cause dry mouth and eyes, fever, joint pain, rashes, and other symptoms. R... | Phase 2 | Recruiting | Drug: Tofacitinib | More Info |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease. | Phase 1 | Recruiting | Drug: CLN-978 | More Info |
| TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE | Sjögren's disease (SjD) is a chronic, immune-mediated, systemic inflammatory disease characterized mainly by involvement of the salivary and lacrimal glands, causing symptoms of sicca syndrome. The disease predominantly affects women (9:1 to 20:1), with a peak incidence between 40 and 60 years of ag... | Phase 4 | Recruiting | Device: Fractional CO2 laser (vaginal) Drug: Promestriene Vaginal | More Info |
| Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies | Unexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and feasible, but only to some extent. Hence, other therapeutic approaches, such a... | N/A | Recruiting | Device: Acupuncture (ACU) Device: Transcutaneous Vagus Nerve Stimulation (tVNS) Other: APA (adapted physical activity ) Device: Acupuncture (sham_ACU) Device: Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) | More Info |
| Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome | This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population. | Phase 4 | Recruiting | Drug: TRYPTYR (Acoltremon ophthalmic solution 0.003%) | More Info |
Top Treatments in Research
| Agent | Class/MOA | Development Status | Company | Company Contact | Clinical Studies | More Information |
|---|---|---|---|---|---|---|
| Ianalumab (VAY736) | Anti-BAFF-R monoclonal antibody — depletes B cells via antibody-dependent cellular cytotoxicity (ADCC) and blocks BAFF-R-mediated survival signaling | Phase 3 | Novartis | Study Director / Novartis | More info | https://clinicaltrials.gov/study/NCT05349214 |
| Deucravacitinib | Selective allosteric TYK2 (tyrosine kinase 2) inhibitor — suppresses type I interferon and IL-12/IL-23 signaling pathways; oral small molecule | Phase 3 | Bristol-Myers Squibb | Study Director / Bristol-Myers Squibb | More info | https://clinicaltrials.gov/study/NCT05946941 |
| IMVT-1402 | Anti-FcRn (neonatal Fc receptor) monoclonal antibody — reduces pathogenic IgG autoantibodies by blocking Fc recycling; subcutaneous administration | Phase 2 | Immunovant | Study Director / Immunovant | More info | https://clinicaltrials.gov/study/NCT06979531 |
| Sibeprenlimab | Anti-APRIL (A proliferation-inducing ligand) monoclonal antibody — blocks B cell survival factor to reduce plasmablast and plasma cell activity | Phase 2 | Otsuka Pharmaceutical | Study Director / Otsuka | More info | https://clinicaltrials.gov/study/NCT06928142 |
| ESG206 | Anti-BAFF-R monoclonal antibody — targets B cell activating factor receptor to selectively deplete autoreactive B cells | Phase 2 | Escugen Biotechnology | Qing Zhou, PhD | More info | https://clinicaltrials.gov/study/NCT07375524 |
| Tofacitinib | JAK1/JAK3 inhibitor — suppresses pro-inflammatory cytokine signaling (IL-6, IFN-γ, IL-17); oral small molecule already approved in other autoimmune conditions | Phase 2 | NIDCR / NIH | Sasha D. Nuby | More info | https://clinicaltrials.gov/study/NCT07281456 |
| CLN-978 | CD19 × CD3 bispecific T cell engager — redirects cytotoxic T cells to deplete CD19+ autoreactive B cells; subcutaneous administration | Phase 1 | Cullinan Therapeutics | Amy Gubits, MPH | More info | https://clinicaltrials.gov/study/NCT07041099 |
† Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 https://rarediseases.info.nih.gov